chevron-down Created with Sketch Beta.
June 17, 2022

FDA Advisory Panel Recommends Emergency Use Authorization for Moderna COVID-19 Vaccine in Children 6-17

On June 14, the FDA Vaccines and Related Biological Products Advisory Committee voted unanimously to recommend emergency use authorization for Moderna’s COVID-19 vaccination for children 6-17 amid a summer spike in COVID-19 cases. Based on scientific data available to the committee, members found that the potential benefits of an additional vaccine for this age group outweighed potential risks. FDA previously authorized the Pfizer-BioNTech vaccine for children ages 12 to 17 in May 2021 and children ages 6-11 in November 2021.

The material in all ABA publications is copyrighted and may be reprinted by permission only. Request reprint permission here.